Checkpoint Inhibitor Refractory Cancer Market Outlook, Trends And Future Opportunities (2023-2030)

Checkpoint Inhibitor Refractory Cancer Market Outlook, Trends And Future Opportunities (2023-2030)

Checkpoint Inhibitor Refractory Cancer Market, By Mechanism of Action (PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors, IDO1 Inhibitors, A2AR Inhibitors, LAG3 Inhibitors, Others), By Cancer Type (Lung Cancer, Melanoma, Renal Cell Carcinoma, Bladder Cancer, Head and Neck Cancer, Hodgkin's Lymphoma, Others), By Route of Administration (Intravenous, Oral, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) The report offers a comprehensive view of the market from supply as well as demand side to help take informed decisions.

  • Published On: Sep 2023
  • Report ID: IDA43
  • Region: Global
  • Format: PDF/EXCEL

Table of Contents

Chapter 1. Research Methodology and Scope

  • Market Segmentation and Scope
  • Regional Coverage
  • Objectives
  • Research Methodology

Chapter 2. Executive Summary

  • Market Landscape
  • Market Size & Forecast
  • Competitive Landscape

Chapter 3. Checkpoint Inhibitor Refractory Cancer Market: By Mechanism of Action Segment Market Trends, Size, and Future Outlook

  • By Mechanism of Action Segment Market Size (US$), CAGR (%), and Forecast (2022-2030)
  • By Mechanism of Action Segment Definitions, Technology Landscape
  • By Mechanism of Action Segment Market Drivers
    • Product Launches
    • Technology Launches
  • By Mechanism of Action Segment Market Restraints

Chapter 4. Checkpoint Inhibitor Refractory Cancer Market: By Cancer Type Segment Market Trends, Size, and Future Outlook

  • By Cancer Type Segment Market Size (US$), CAGR (%), and Forecast (2022-2030)
  • By Cancer Type Segment Definitions, Technology Landscape
  • By Cancer Type Segment Market Drivers
    • Product Launches
    • Technology Launches
  • By Cancer Type Segment Market Restraints

Chapter 5. Checkpoint Inhibitor Refractory Cancer Market: By Route of Administration Segment Market Trends, Size, and Future Outlook

  • By Route of Administration Segment Market Size (US$), CAGR (%), and Forecast (2022-2030)
  • By Route of Administration Segment Definitions, Technology Landscape
  • By Route of Administration Segment Market Drivers
    • Product Launches
    • Technology Launches
  • By Route of Administration Segment Market Restraints

Chapter 6. Checkpoint Inhibitor Refractory Cancer Market: By Distribution Channel Segment Market Trends, Size, and Future Outlook

  • By Distribution Channel Segment Market Size (US$), CAGR (%), and Forecast (2022-2030)
  • By Distribution Channel Segment Definitions, Technology Landscape
  • By Distribution Channel Segment Market Drivers
    • Product Launches
    • Technology Launches
  • By Distribution Channel Segment Market Restraints

Chapter 7. Checkpoint Inhibitor Refractory Cancer Market: Regional Market Trends, Size, and Future Outlook

  • North America Market Size (US$), CAGR (%), and Forecast (2022-2030)
    • North America Definitions, Technology Landscape
    • North America Market Drivers
    • North America Market Restraints
    • Competitive Outlook
  • Europe Market Size (US$), CAGR (%), and Forecast (2022-2030)
    • Europe Definitions, Technology Landscape
    • Europe Market Drivers
    • Europe Market Restraints
    • Competitive Outlook
  • Asia Pacific Market Size (US$), CAGR (%), and Forecast (2022-2030)
    • Asia Pacific Definitions, Technology Landscape
    • Asia Pacific Market Drivers
    • Asia Pacific Market Restraints
    • Competitive Outlook
  • Rest of World Market Size (US$), CAGR (%), and Forecast (2022-2030)
    • Rest of World Definitions, Technology Landscape
    • Rest of World Market Drivers
    • Rest of World Market Restraints
    • Competitive Outlook

Chapter 8. Checkpoint Inhibitor Refractory Cancer Market: Competitive Landscape

  • Merck
    • Company Overview
    • Financial Overview
    • Product Portfolio
    • Strategies
  • Amgen
    • Company Overview
    • Financial Overview
    • Product Portfolio
    • Strategies
  • AstraZeneca
    • Company Overview
    • Financial Overview
    • Product Portfolio
    • Strategies
  • Roche
    • Company Overview
    • Financial Overview
    • Product Portfolio
    • Strategies
  • Pfizer
    • Company Overview
    • Financial Overview
    • Product Portfolio
    • Strategies
  • Novartis
    • Company Overview
    • Financial Overview
    • Product Portfolio
    • Strategies
  • AbbVie
    • Company Overview
    • Financial Overview
    • Product Portfolio
    • Strategies
  • GlaxoSmithKline
    • Company Overview
    • Financial Overview
    • Product Portfolio
    • Strategies
  • Sanofi
    • Company Overview
    • Financial Overview
    • Product Portfolio
    • Strategies
  • Gilead Sciences
    • Company Overview
    • Financial Overview
    • Product Portfolio
    • Strategies
  • Takeda
    • Company Overview
    • Financial Overview
    • Product Portfolio
    • Strategies
  • Bristol-Myers Squibb
    • Company Overview
    • Financial Overview
    • Product Portfolio
    • Strategies
  • Merck KGaA
    • Company Overview
    • Financial Overview
    • Product Portfolio
    • Strategies
  • Regeneron
    • Company Overview
    • Financial Overview
    • Product Portfolio
    • Strategies
  • Moderna
    • Company Overview
    • Financial Overview
    • Product Portfolio
    • Strategies
  • Johnson & Johnson
    • Company Overview
    • Financial Overview
    • Product Portfolio
    • Strategies
  • Eli Lilly
    • Company Overview
    • Financial Overview
    • Product Portfolio
    • Strategies
  • Bayer
    • Company Overview
    • Financial Overview
    • Product Portfolio
    • Strategies
  • Daiichi Sankyo
    • Company Overview
    • Financial Overview
    • Product Portfolio
    • Strategies
  • Eisai
    • Company Overview
    • Financial Overview
    • Product Portfolio
    • Strategies

Research Methodology

  • Primary Research
  • Secondary Research
  • Assumptions
  • IDataAcumen Analysis
  • Paid Databases

Appendix

  • About Us

Frequently Asked Questions

The current market size of the checkpoint inhibitor refractory cancer market is estimated at USD 3.4 billion in 2023.

Increasing cancer prevalence globally, rising cases of resistance to checkpoint inhibitors, Strong R&D focus and pipeline products, Advances in combination therapies, Emergence of niche inhibitors and novel platforms, Growing diagnostic capabilities

Major players in Checkpoint Inhibitor Refractory Cancer Market: Merck, Amgen, AstraZeneca, Roche, Pfizer, Novartis, AbbVie, GlaxoSmithKline, Sanofi, Gilead Sciences, Takeda, Bristol-Myers Squibb, Merck KGaA, Regeneron, Moderna, Johnson & Johnson, Eli Lilly, Bayer, Daiichi Sankyo, Eisai

CAGR of 27.8% and market size of USD 19.1 billion by 2030